{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:13:26Z","timestamp":1792134806663,"version":"4.4.0"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.2967\/jnumed.122.264741","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T17:20:15Z","timestamp":1671124815000},"page":"731-737","source":"Crossref","is-referenced-by-count":46,"title":["Is\n                    <sup>18<\/sup>\n                    F-FDG PET Needed to Assess\n                    <sup>177<\/sup>\n                    Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis"],"prefix":"10.2967","volume":"64","author":[{"given":"Robert","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce","family":"Telli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip H.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"2023042807151168000_64.5.731.1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cpet.2021.03.004","article-title":"Prostate cancer theranostics: PSMA targeted therapy","volume":"16","author":"Seifert","year":"2021","journal-title":"PET Clin."},{"key":"2023042807151168000_64.5.731.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023042807151168000_64.5.731.3","unstructured":"EAU. EAU guideline prostate cancer. https:\/\/uroweb.org\/guidelines\/prostate-cancer. Accessed March 10, 2022."},{"key":"2023042807151168000_64.5.731.4","unstructured":"NCCN. NCCN guideline prostate cancer. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459. Accessed January 10, 2022."},{"key":"2023042807151168000_64.5.731.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2023042807151168000_64.5.731.6","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol."},{"key":"2023042807151168000_64.5.731.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263638"},{"key":"2023042807151168000_64.5.731.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263441"},{"key":"2023042807151168000_64.5.731.9","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023042807151168000_64.5.731.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023042807151168000_64.5.731.11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023042807151168000_64.5.731.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2023042807151168000_64.5.731.13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023042807151168000_64.5.731.14","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"2023042807151168000_64.5.731.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263035"},{"key":"2023042807151168000_64.5.731.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1754"},{"key":"2023042807151168000_64.5.731.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0563"},{"key":"2023042807151168000_64.5.731.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.3553"},{"key":"2023042807151168000_64.5.731.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233429"},{"key":"2023042807151168000_64.5.731.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7270"},{"key":"2023042807151168000_64.5.731.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263274"},{"key":"2023042807151168000_64.5.731.22","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177 Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics."},{"key":"2023042807151168000_64.5.731.23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","article-title":"Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy","volume":"2","author":"Thang","year":"2019","journal-title":"Eur Urol Oncol."},{"key":"2023042807151168000_64.5.731.24","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics."},{"key":"2023042807151168000_64.5.731.25","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.3390\/cancers13164134","article-title":"Value of combined PET imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [177Lu]Lu-PSMA-617 RLT","volume":"13","author":"Khreish","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2023042807151168000_64.5.731.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262371"},{"key":"2023042807151168000_64.5.731.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.262250"},{"key":"2023042807151168000_64.5.731.28","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023042807151168000_64.5.731.29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"2023042807151168000_64.5.731.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"2023042807151168000_64.5.731.31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13550-021-00845-z","article-title":"Intraindividual comparison of [68Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis","volume":"11","author":"Hober\u00fcck","year":"2021","journal-title":"EJNMMI Res."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T10:18:22Z","timestamp":1682677102000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,4,28]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.2967\/jnumed.122.264741"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264741","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}